BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29748334)

  • 1. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
    Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
    Tourdot BE; Conaway S; Niisuke K; Edelstein LC; Bray PF; Holinstat M
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2644-50. PubMed ID: 25278289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
    Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
    Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
    Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
    Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
    Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
    French SL; Thalmann C; Bray PF; Macdonald LE; Murphy AJ; Sleeman MW; Hamilton JR
    Blood Adv; 2018 Jun; 2(11):1283-1293. PubMed ID: 29884748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
    Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
    J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.
    Denorme F; Armstrong ND; Stoller ML; Portier I; Tugolukova EA; Tanner RM; Montenont E; Bhatlekar S; Cody M; Rustad JL; Ajanel A; Tolley ND; Murray DC; Boyle JL; Nieman MT; McKenzie SE; Yost CC; Lange LA; Cushman M; Irvin MR; Bray PF; Campbell RA
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37471144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
    J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
    Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
    Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
    Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
    J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the antiplatelet effect of aspirin.
    Würtz M; Kristensen SD; Hvas AM; Grove EL
    Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
    Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
    J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
    Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
    Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
    Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR
    Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.